KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Research & Development (2018 - 2025)

Castle Biosciences' Research & Development history spans 7 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 14.8% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $51.8 million, changed 0.37%, while the annual FY2025 figure was $51.8 million, 0.37% changed from the prior year.
  • Research & Development for Q4 2025 was $13.5 million at Castle Biosciences, up from $13.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.4 million in Q1 2023 and bottomed at $5.9 million in Q1 2021.
  • The 5-year median for Research & Development is $12.5 million (2024), against an average of $11.6 million.
  • The largest annual shift saw Research & Development skyrocketed 151.22% in 2021 before it decreased 9.54% in 2025.
  • A 5-year view of Research & Development shows it stood at $9.4 million in 2021, then rose by 19.74% to $11.3 million in 2022, then grew by 14.9% to $13.0 million in 2023, then dropped by 9.4% to $11.8 million in 2024, then rose by 14.8% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Research & Development are $13.5 million (Q4 2025), $13.0 million (Q3 2025), and $12.8 million (Q2 2025).